Clinical trial
A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia
NCT01508910 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia
- Lead sponsor
- Lisata Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2012
- Completion date
- November 30, 2015
- Enrollment
- 291 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.
advanced coronary heart disease, chronic myocardial ischemia, refractory angina pectoris